A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This study is a double-blind, randomized, placebo-controlled (2:1 niraparib:placebo) study
in patients with Stage III or IV ovarian cancer. Patients must have completed front-line
platinum based regimen with a physician-assessed response of Complete Response (CR) or
Partial Response (PR). Stage III patients must have visual evidence of disease.
Additionally, patients must have a normal or >90% decrease in cancer antigen 125 (CA-125)
following front-line platinum treatment. The study will assess the efficacy of niraparib as
maintenance treatment, as measured by PFS.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society